01/08/2025
Happy New Year!
As many of you have heard, there is a new combination CFTR modulator drug recently approved by the FDA called ALYFTREK (TM). For those of you who were not previously eligible for a modulator, but now are eligible, we will reach out to you individually to schedule an appointment to discuss initiating therapy.
For those of you who are already on TRIKAFTA®, the new drug is expected to be very similar in benefit as TRIKAFTA (e.g. based on the clinical trials, we do not expect your lung function to improve further), but ALYFTREK will be dosed once daily. In the clinical trials, side effects for ALYFTREK were similar to the ones reported in the TRIKAFTA trials. It is not yet known if people who did not tolerate TRIKAFTA will be able to tolerate ALYFTREK better.
ALYFTREK will be available in some pharmacies in the next few weeks but may take longer in other cases. ALYFTREK is expected to be more expensive than TRIKAFTA, and we do not yet know which insurance plans will allow patients to switch if they are currently doing well on TRIKAFTA. We expect that many people with CF that are doing well on TRIKAFTA will wish to continue their current therapy, and that others would be interested in trying ALYFTREK. We are happy to discuss these options with you at your next visit.
For those of you who are not eligible for any CFTR modulators, we are continuing to do research to find a drug that will help you. Please reach out to your doctor or to the research team if you would like to participate in a clinical trial.
Best wishes
The Colorado Adult CF Program Team
